| Bioactivity | Liraglutide-13C5,15N (tetraTFA)is the 13C and 15N labeledLiraglutide(HY-P0014)[1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus[2]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | Liraglutide-13C5,15N tetraTFA |
| Shortening | HAEGTFTSD-{Val-13C5,15N}-SSYL-{N6-[N-(1-oxohexadecyl)-L-γ-Etamyl]-Glu}-GQAAKEFIAWLVRGRG (TFA salt) |
| Formula | C17613C5H271F12N4215NO59 |
| Molar Mass | 4227.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |
Liraglutide-13C5,15N tetraTFA
CAS: F: C17613C5H271F12N4215NO59 W: 4227.28
Liraglutide-13C5,15N (tetraTFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.